<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659787</url>
  </required_header>
  <id_info>
    <org_study_id>14-0170</org_study_id>
    <nct_id>NCT02659787</nct_id>
  </id_info>
  <brief_title>Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology</brief_title>
  <acronym>BED</acronym>
  <official_title>Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to to study the effects of buprenorphine, a partial mu-opioid agonist, on
      depressed mood in a healthy young adults with a range of depressive symptomatology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown that opioid analgesics, particularly the mu-opioid partial agonist
      buprenorphine, have anti-depressant properties in laboratory animal models. In humans, rates
      of prescription opioid abuse are significantly higher in patients with depression. This
      suggests that individuals with negative mood states (e.g., depressive states) may respond
      more positively to opioid drugs. A handful of small studies in in humans have suggested that
      buprenorphine reduces symptoms of depression in patients who did not respond to standard
      anti-depressants, and laboratory studies have shown buprenorphine may reduce responses to
      some types of negative stimuli and enhance responses to positive stimuli. However, a
      controlled laboratory study assessing potential anti-depressant effects of an opioid
      medication has never been conducted. In this project, the investigators propose to examine
      depressive symptomatology as a predictor of subjective mood responses to buprenorphine, using
      two measures; i) self-reported depressive symptomatology as measured by the Beck Depression
      Inventory (BDI-II), and ii) physiological indices of depressive symptomatology as measured by
      heart rate variability. Reduced heart rate variability has been shown to be associated with
      depression, and such a physiological measure may allow for the detection of more subtle
      effects than would a self-report questionnaire alone. Healthy volunteers (N=60) will first
      complete the BDI and provide baseline measures of heart rate variability. Then they will
      attend two laboratory sessions, at which they will receive placebo or 0.2mg buprenorphine.
      The investigators have tested these low doses of buprenorphine in previous studies, and they
      produce measurable changes in mood and behavior in healthy volunteers. The investigators will
      collect measures of mood and physiological drug response (pupillometry, heart rate, and blood
      pressure) at regular intervals throughout each session, and will then examine their baseline
      indices of depressive symptomatology in relation to responses to the drug. The central
      hypothesis is that individuals with greater self-reported depressive symptoms and lower heart
      rate variability will experience the greatest enhancement of mood in response to
      buprenorphine. It is expected that this work will provide a better understanding of which
      individuals are most likely to experience positive mood effects in response to opioid drugs,
      and may therefore be at-risk for developing an opioid use disorder. Furthermore, it may lay
      the foundation for future research in the development of novel opioid-based treatments for
      depression.

      Design: The study will use a 3-session within-subjects double-blind design in which
      participants will receive single doses of buprenorphine (0, 0.2 mg sublingual) in randomized
      order. All screening, orientation, and study session procedures will take place in the Human
      Behavioral Pharmacology Laboratory suite in the L4 wing of 5841 S. Maryland Ave.

      Drug and Doses: Investigators will administer placebo, 0.2 mg buprenorphine (Temgesic) via
      sublingual tablet in counterbalanced order under double-blind conditions. These tablets
      dissolve within 5-8 minutes. This drug has been approved for treatment of severe pain. The
      onset of action after sublingual administration is 30 minutes, with a peak plasma
      concentration at 1/5-2 hours and a half-life of 5 hours. The dose of buprenorphine are very
      low, and the average maintenance dose for opioid abusers is 8 mg. Doses will be separated by
      at least 72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Response With and Without Buprenorphine</measure>
    <time_frame>0 through 3 hours after dosing.</time_frame>
    <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Low dose buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects all receive placebo, 0.2 mg buprenorphine in crossover design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects all receive placebo, 0.2 mg buprenorphine in crossover design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2mg Buprenorphine</intervention_name>
    <description>Sublingual buprenorphine tablets (0.2mg)</description>
    <arm_group_label>Low dose buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers

          -  High school education

          -  Fluency in English

          -  BMI between 19 and 30

        Exclusion Criteria:

          -  Medical conditions contraindicating study participation

          -  Regularly medication use

          -  Current or past opioid abuse or dependence

          -  Current or past drug or alcohol dependence

          -  Psychiatric illness

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl). 2015 Mar;232(5):907-15. doi: 10.1007/s00213-014-3723-y. Epub 2014 Sep 3.</citation>
    <PMID>25178815</PMID>
  </reference>
  <reference>
    <citation>Sullivan MD, Edlund MJ, Steffick D, Un√ºtzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005 Dec 15;119(1-3):95-103. Epub 2005 Nov 17.</citation>
    <PMID>16298066</PMID>
  </reference>
  <reference>
    <citation>Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF 3rd. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014 Aug;75(8):e785-93. doi: 10.4088/JCP.13m08725.</citation>
    <PMID>25191915</PMID>
  </reference>
  <reference>
    <citation>Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008 Oct;28(5):593-5. doi: 10.1097/JCP.0b013e31818638a4.</citation>
    <PMID>18794671</PMID>
  </reference>
  <reference>
    <citation>Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995 Feb;15(1):49-57.</citation>
    <PMID>7714228</PMID>
  </reference>
  <reference>
    <citation>Striebel JM, Kalapatapu RK. The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med. 2014;47(2):169-74. doi: 10.2190/PM.47.2.g.</citation>
    <PMID>25084802</PMID>
  </reference>
  <reference>
    <citation>Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, van Dyck R, Penninx BW. Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Arch Gen Psychiatry. 2008 Dec;65(12):1358-67. doi: 10.1001/archpsyc.65.12.1358.</citation>
    <PMID>19047522</PMID>
  </reference>
  <reference>
    <citation>Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Panksepp J, Malcolm-Smith S, Thomas K, Stein DJ, van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology. 2013 Jan;38(1):166-70. doi: 10.1016/j.psyneuen.2012.05.002. Epub 2012 May 30.</citation>
    <PMID>22651957</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 27, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02659787/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then Buprenorphine</title>
          <description>Participants first received placebo during first study session. After a washout period of 3 days, participants returned to lab and they then received 0.2 mg buprenorphine (Sublingual buprenorphine tablets (0.2mg).</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine, Then Placebo</title>
          <description>Participants first received 0.2 mg buprenorphine (Sublingual buprenorphine tablets (0.2mg) during first study session. After a washout period of 3 days, participants returned to lab and they received placebo tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALL Subjects</title>
          <description>Subjects all receive placebo, 0.2 mg buprenorphine in crossover design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Response With and Without Buprenorphine</title>
        <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
        <time_frame>0 through 3 hours after dosing.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Buprenorphine</title>
            <description>Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
0.2mg Buprenorphine: Sublingual buprenorphine tablets (0.2mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Response With and Without Buprenorphine</title>
          <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feel Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.03" spread="3.32"/>
                    <measurement group_id="O2" value="10.64" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.09" spread="3.97"/>
                    <measurement group_id="O2" value="19.8" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.91" spread="2.44"/>
                    <measurement group_id="O2" value="5.74" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Want More</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.46" spread="3.90"/>
                    <measurement group_id="O2" value="16.76" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 days for each intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo, Then Buprenorphine</title>
          <description>Participants first received placebo during first study session. After a washout period of 3 days, participants returned to lab and they then received 0.2 mg buprenorphine (sublingual buprenorphine tablets (0.2 mg).</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine, Then Placebo</title>
          <description>Participants first received 0.2 mg buprenorphine (Sublingual buprenorphine tablets (0.2 mg)) during first study session. After a washout period of 3 days, participants returned to lab and they then received placebo tablet.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Harriet de Wit</name_or_title>
      <organization>University of Chicago</organization>
      <phone>7737023560</phone>
      <email>dewitlab@yoda.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

